Qinghai Spring Medicinal Resources Technology Co Ltd Cash Flow-to-Debt Ratio
Qinghai Spring Medicinal Resources Technology Co Ltd cash flow-to-debt ratio. Qinghai Spring Medicinal Resources Technology Co Ltd (600381) has a Cash Flow-to-Debt Ratio of -0.18x as of September 2025, meaning its operating cash flow of CN¥-8.22 Million could theoretically repay 0% of its total liabilities (CN¥45.34 Million) in one year. Check 600381 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Qinghai Spring Medicinal Resources Technology Co Ltd (1999–2025)
Cash flow-to-debt ratio of Qinghai Spring Medicinal Resources Technology Co Ltd from 1999 to 2025. Historical debt coverage capacity for Qinghai Spring Medicinal Resources Technology Co Ltd across 27 annual periods. Check Qinghai Spring Medicinal Resources Techn cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Qinghai Spring Medicinal Resources Technology Co Ltd Cash Flow-to-Debt Ratio by Year (1999–2025)
Qinghai Spring Medicinal Resources Technology Co Ltd cash flow-to-debt ratio by year from 1999 to 2025. Year-by-year debt coverage analysis for Qinghai Spring Medicinal Resources Technology Co Ltd. For the full cash flow conversion analysis, see Qinghai Spring Medicinal Resources Techn cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.59x | CN¥-26.41 Million | CN¥44.87 Million | ▼ -193.1% |
| 2024 | 0.63x | CN¥80.97 Million | CN¥128.02 Million | ▲ +143.3% |
| 2023 | 0.26x | CN¥23.92 Million | CN¥91.99 Million | ▲ +121.5% |
| 2022 | -1.21x | CN¥-31.82 Million | CN¥26.30 Million | ▲ +47.7% |
| 2021 | -2.31x | CN¥-63.93 Million | CN¥27.64 Million | ▼ -306.8% |
| 2020 | -0.57x | CN¥-77.95 Million | CN¥137.08 Million | ▲ +95.2% |
| 2019 | -11.74x | CN¥-236.30 Million | CN¥20.14 Million | ▼ -236.1% |
| 2018 | -3.49x | CN¥-183.97 Million | CN¥52.68 Million | ▼ -514.2% |
| 2017 | 0.84x | CN¥95.74 Million | CN¥113.56 Million | ▼ -49.4% |
| 2016 | 1.67x | CN¥344.99 Million | CN¥206.95 Million | ▼ -29.0% |
| 2015 | 2.35x | CN¥832.17 Million | CN¥354.60 Million | ▲ +3049.9% |
| 2014 | -0.08x | CN¥-89.64 Million | CN¥1.13 Billion | ▼ -307.5% |
| 2013 | -0.02x | CN¥-28.09 Million | CN¥1.44 Billion | ▲ +94.7% |
| 2012 | -0.37x | CN¥-701.18 Million | CN¥1.90 Billion | ▼ -338.9% |
| 2011 | 0.15x | CN¥249.98 Million | CN¥1.62 Billion | ▲ +102.9% |
| 2010 | 0.08x | CN¥71.47 Million | CN¥938.58 Million | ▲ +2.2% |
| 2009 | 0.07x | CN¥39.16 Million | CN¥525.60 Million | ▲ +110.7% |
| 2008 | 0.04x | CN¥20.83 Million | CN¥589.02 Million | ▲ +257.7% |
| 2007 | 0.01x | CN¥7.00 Million | CN¥707.61 Million | ▼ -60.4% |
| 2006 | 0.02x | CN¥21.57 Million | CN¥863.38 Million | ▼ -83.9% |
| 2005 | 0.16x | CN¥162.12 Million | CN¥1.05 Billion | ▲ +461.1% |
| 2004 | 0.03x | CN¥33.83 Million | CN¥1.22 Billion | ▲ +1430.8% |
| 2003 | 0.00x | CN¥1.43 Million | CN¥789.85 Million | ▼ -95.2% |
| 2002 | 0.04x | CN¥15.54 Million | CN¥415.90 Million | ▲ +193.0% |
| 2001 | -0.04x | CN¥-10.64 Million | CN¥264.94 Million | ▼ -267.0% |
| 2000 | 0.02x | CN¥4.52 Million | CN¥187.91 Million | ▼ -95.6% |
| 1999 | 0.55x | CN¥70.28 Million | CN¥128.04 Million | — |